Collaboration, License, and Other Agreements - North America - General Information (Details) $ in Thousands	3 Months Ended	6 Months Ended
Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) item	Jun. 30, 2021 USD ($)
Collaboration, License, Promotion and Other Commercial Agreements
Research and development expense	$ 11,452	$ 12,163	$ 22,274	$ 27,647
AbbVie
Collaboration, License, Promotion and Other Commercial Agreements
Sales-related milestone if certain conditions are met	80,000		$ 80,000
Remaining commercial-period performance obligations \| item			3
Cost sharing amount, reduction to research and development	2,100	2,800	$ 4,500	5,700
Collaborative arrangement, percentage of obligation of development costs incurred			50.00%
Percentage of net profit from commercialization (as a percent)			50.00%
Percentage of net loss from commercialization (as a percent)			50.00%
North America \| AbbVie
Collaboration, License, Promotion and Other Commercial Agreements
Research and development expense	$ 2,000	$ 1,800	$ 3,700	$ 3,600

Represents the percentage of net loss from commercialization.

No definition available.

Name:	irwd_CollaborativeArrangementPercentageOfNetLoss
Namespace Prefix:	irwd_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of net profit from commercialization.

+ References

No definition available.

+ Details

Name:	irwd_CollaborativeArrangementPercentageOfNetProfit
Namespace Prefix:	irwd_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Percentage of Obligation of Development Costs Incurred

+ References

No definition available.

+ Details

Name:	irwd_CollaborativeArrangementPercentageOfObligationOfDevelopmentCostsIncurred
Namespace Prefix:	irwd_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Contingent sales-related milestone receivable.

+ References

No definition available.

+ Details

Name:	irwd_ContingentSalesRelatedMilestoneReceivable
Namespace Prefix:	irwd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the reduction to research and development expense for the amount received from the collaboration partner under cost sharing provisions.

+ References

No definition available.

+ Details

Name:	irwd_CostSharingArrangementReductionToResearchAndDevelopmentExpense
Namespace Prefix:	irwd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of Remaining Commercial Period Performance Obligations.

+ References

No definition available.

+ Details

Name:	irwd_NumberOfRemainingCommercialPeriodPerformanceObligations
Namespace Prefix:	irwd_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=irwd_AbbviePlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=srt_NorthAmericaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: